Drug Trial Radar · NCT07777133
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Dec 5, 2026
Study completion Dec 5, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of \[14C\]Navlimetostat (BMS-986504) in healthy female participants
Conditions
- Healthy Female Participants
Interventions
NavlimetostatDrug
Specified dose on specified days
[14C]NavlimetostatDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 14 days
- Time of maximum observed plasma concentration (Tmax)Time frame: Up to 14 days
- Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))Time frame: Up to 14 days
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to 14 days
- Terminal elimination half-life (T-HALF)Time frame: Up to 14 days
- Apparent total body clearance (CLT/F)Time frame: Up to 14 days
- Apparent volume of distribution during the terminal phase (VZ/F)Time frame: Up to 14 days
- Percent of plasma navlimetostat AUC(INF) to plasma radioactivity AUC(INF) (%AUC(INF))Time frame: Up to 14 days
- Total radioactivity (TRA) ratio of blood AUC(INF) to plasma AUC(INF)Time frame: Up to 14 days
- Total amount of dose recovered in urine (UR)Time frame: Up to 14 days
- Percent of administered dose recovered in urine (%UR)Time frame: Up to 14 days
- Renal clearance (CLR)Time frame: Up to 14 days
- TRA from URTime frame: Up to 14 days
- TRA from %URTime frame: Up to 14 days
- TRA from total amount of dose recovered in feces (FR)Time frame: Up to 14 days
- TRA from percent of administered dose recovered in feces (%FR)Time frame: Up to 14 days
- TRA from total amount of radioactivity recovered (Rtotal)Time frame: Up to 14 days
- TRA from total percent of radioactivity recovered (%TOTAL)Time frame: Up to 14 days
- TRA amount recovered of the radioactive dose in vomit, if applicableTime frame: Up to 14 days
- TRA fraction of the radioactive dose in vomit, if applicableTime frame: Up to 14 days
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 0002
Madison, Wisconsin · Not yet recruiting
ICON Netherlands - Groningen
Groningen, Provincie Groningen, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.